Circulating leptin is associated with serum uric acid level and its tubular reabsorption in a sample of adult middle-aged men
- 7 Downloads
Leptin is associated with cardiovascular risk factors (e.g. hypertension, insulin resistance, kidney disease and excess body weight). Experimental studies showed that leptin might affect serum uric acid, by modulation of the uric acid excretion. However, there are few observational data on the relationship between leptin and uric acid in the general population. Therefore, the aim of the present study was to evaluate the relationship between leptin and uric acid and its excretion in a large middle-aged male general population.
A sample of 930 adult male individuals (mean age: 52 years) without therapy for high uric acid was included in the analysis (the Olivetti Heart Study).
Uric acid was significantly and positively associated with blood pressure, BMI, waist circumference, insulin resistance, C-reactive protein and leptin (p < 0.01), while inversely with renal function (p = 0.01). The multivariate analysis confirmed the association between leptin and uric acid after adjustment for potential confounders (p < 0.01). After division for adiposity, this trend was confirmed separately for normal weight and excess body weight participants. Moreover, leptin was inversely associated with excretion of uric acid (p < 0.01), also in multivariate analysis (p = 0.03).
The results of this study indicate a positive association between circulating leptin levels and uric acid, independently of potential confounders, both in normal and excess body weight men. Furthermore, an inverse association between leptin and uric acid excretion was detected.
KeywordsCardiovascular risk Uric acid Uric acid excretion Adipocytokines Adipokines Leptin
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study protocol was approved by the Ethics Committee of “Federico II” University in Naples.
All participants provided their informed written consent to participate.
- 7.D’Elia L, Manfredi M, Perna L, Iacone R, Russo O, Strazzullo P, Galletti F (2018) Circulating leptin levels predict the decline in renal function with age in a sample of adult men (The Olivetti Heart Study). Intern Emerg Med. https://doi.org/10.1007/s11739-018-1924-9 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.De Pergola G, Giagulli VA, Bartolomeo N, Gaeta F, Petruzzella A, Guastamacchia E, Triggiani V, Silvestris F (2017) Independent relationship between serum osteocalcin and uric acid in a cohort of apparently healthy obese subjects. Endocr Metab Immune Disord Drug Targets 17(3):207–212. https://doi.org/10.2174/1871530317666170825164415 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.De Pergola G, Cortese F, Termine G, Meliota G, Carbonara R, Masiello M, Cortese AM, Silvestris F, Caccavo D, Ciccone MM (2018) Uric acid, metabolic syndrome and atherosclerosis: the chicken or the egg, which comes first? Endocr Metab Immune Disord Drug Targets 18(3):251–259. https://doi.org/10.2174/1871530318666180212101548 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Caulfield MJ, Munroe PB, O’Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, Shaw-Hawkins S, Dobson RJ, Wallace C, Newhouse SJ, Brown M, Connell JM, Dominiczak A, Farrall M, Lathrop GM, Samani NJ, Kumari M, Marmot M, Brunner E, Chambers J, Elliott P, Kooner J, Laan M, Org E, Veldre G, Viigimaa M, Cappuccio FP, Ji C, Iacone R, Strazzullo P, Moley KH, Cheeseman C (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 5(10):e197. https://doi.org/10.1371/journal.pmed.0050197 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Testa A, Prudente S, Leonardis D, Spoto B, Sanguedolce MC, Parlongo RM et al (2015) A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. Nutr Metab Cardiovasc Dis 25(12):1087–1094. https://doi.org/10.1016/j.numecd.2015.08.004 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36(10):1953–2041PubMedCrossRefGoogle Scholar
- 33.Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM (2018) Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis 71(6):851–865PubMedCrossRefGoogle Scholar
- 34.Desideri G, Virdis A, Casiglia E, Borghi C, Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (2018) Exploration into uric and cardiovascular disease: Uric Acid Right for heArt Health [URRAH] Project, a study protocol for a retrospective observational study. High Blood Press Cardiovasc Prev 25(2):197–202PubMedCrossRefGoogle Scholar
- 37.Jackson EK, Li P (1997) Human leptin has natriuretic activity in the rat. Am J Physio 1272:F333–F338Google Scholar
- 48.Vickers SP, Cheetham SC, Headland KR et al (2014) Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes 7:265–275PubMedPubMedCentralCrossRefGoogle Scholar